ZUG, Switzerland, May 4, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to
developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its
financial results for the first quarter of 2016 on Wednesday, May 11, 2016. Following the announcement, Auris Medical's management
team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the Company's
financial results and to provide a general business update.
To participate in this conference call, dial 1-855-217-7942 (USA) or +1-646-254-3374 (International), and enter passcode
9629643. A live webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at
www.aurismedical.com. A replay will be available approximately two hours following the live
call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important
unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear
tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel
formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003
and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global
Market under the symbol "EARS".
Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, investors@aurismedical.com
HUG#2009441
